Filtered By:
Condition: Headache
Countries: Japan Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 33 results found since Jan 2013.

Scientists tie third clinical trial death to experimental Alzheimer ’s drug
As enthusiasm mounts for a new experimental antibody that appears to slow cognitive decline in some Alzheimer’s patients, a third death linked to the drug during its clinical testing may amplify concerns about its safety. Science has obtained medical records showing a 79-year-old Florida woman participating in an ongoing trial of the antibody died in mid-September after experiencing extensive brain swelling and bleeding, as well as seizures. Multiple neuroscientists who reviewed the records at Science ’s request believe her death was likely caused by the antibody, lecanemab. “The brain swelling and t...
Source: ScienceNOW - December 21, 2022 Category: Science Source Type: news

As some hail new antibody treatment for Alzheimer ’s, safety and benefit questions persist
In a packed San Francisco conference room with a celebratory atmosphere, upbeat company representatives and scientists yesterday presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp of being greenlit by the U.S. Food and Drug Administration (FDA). Yet other researchers warn of potential risks, including brain swelling and brain hemorrhages that were linked to the recently disclosed deaths of two trial participants wh...
Source: Science of Aging Knowledge Environment - December 1, 2022 Category: Geriatrics Source Type: research

Second death linked to potential antibody treatment for Alzheimer ’s disease
A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a massive brain hemorrhage that some researchers link to the drug. The clinical trial death, described in an unpublished case report Science has obtained, is the second thought to be associated with the antibody called lecanemab. The newly disclosed fatality intensifies questions about its safety and how widely lecanemab should be prescribed if ultimately approved by regulators. The woman, who received infusions of the antibody as part of the trial, s...
Source: ScienceNOW - November 28, 2022 Category: Science Source Type: news

Actual Telemedicine Needs of Japanese Patients with Neurological Disorders in the COVID-19 Pandemic
Conclusion We can contribute to the management of the COVID-19 pandemic and the medical economy by promoting telemedicine, especially for young patients with headaches or epilepsy.PMID:36418105 | DOI:10.2169/internalmedicine.9702-22
Source: Internal Medicine - November 23, 2022 Category: Internal Medicine Authors: Ryo Sasaki Taijun Yunoki Yumiko Nakano Yusuke Fukui Mami Takemoto Ryuta Morihara Koji Abe Toru Yamashita Source Type: research

Genetic spectrum of NOTCH3 and clinical phenotype of CADASIL patients in different populations
CONCLUSION: The findings help to better understand the clinical variability and genetic heterogeneity of CADASIL.PMID:35822697 | DOI:10.1111/cns.13917
Source: CNS Neuroscience and Therapeutics - July 13, 2022 Category: Neuroscience Authors: Wang Ni Yi Zhang Liang Zhang Juan-Juan Xie Hong-Fu Li Zhi-Ying Wu Source Type: research

Epidemiology of Moyamoya Angiopathy in Eastern India
ConclusionMMA is an important etiological consideration in patients with stroke, especially in children. It can present with a myriad of transient neurological symptoms, frequently overlooked, leading to delayed diagnosis, and contributing to socio-economic burden. Indian MMA showed aberrations in its gender predisposition, age distribution, frequency of familial cases, disease manifestation, and type of stroke, in comparison to its Japanese and Caucasian counterparts pointing to the inter- and intra-continent differences of MMA phenotype. Future development of the Indian MMA national registry is of essence.
Source: Frontiers in Neurology - March 4, 2022 Category: Neurology Source Type: research